Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 37Withdrawn 5Unknown 2Recruiting 2Active not recruiting 2Terminated 1Suspended 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 5Tumor-Agnostic 2Thoracic 2Sarcoma 2Other hematologic neoplasm 2Dermatologic 2Breast 2Plasma cell 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 2

Interventions

pembrolizumab 72Nivolumab 49Ipilimumab 29Specimen Handling 15Magnetic Resonance Spectroscopy 15trametinib 14Biopsy 13dabrafenib 11cemiplimab 11avelumab 11binimetinib 10Radiotherapy 10Cyclophosphamide 10CTLA-4 Antigen 9fludarabine 7encorafenib 7atezolizumab 7Radiosurgery 7Immunoglobulin G 7Disulfides 7Cisplatin 7lenvatinib 6durvalumab 6Paclitaxel 6Carboplatin 6tislelizumab 5relatlimab 5fludarabine phosphate 5dostarlimab 5Pemetrexed 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × sargramostim × Dermatologic × Clear all
NCT02339571 2026-05-13

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
600 enrolled
Dermatologic

Melanoma

NCT01134614 2026-04-28

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
245 enrolled 8 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡